Atossa Therapeutics Announces Updated Protocol For Clinical Trial Evaluating (Z)-Endoxifen In Combination With Abemaciclib In Women With ER+/HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics announced protocol changes in its clinical trial evaluating (Z)-endoxifen in combination with Eli Lilly's abemaciclib for treating ER+/HER2- breast cancer.
June 28, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics announced protocol changes in its clinical trial evaluating (Z)-endoxifen in combination with abemaciclib for treating ER+/HER2- breast cancer.
The protocol changes in the clinical trial could potentially accelerate the development and approval process for Atossa's (Z)-endoxifen, positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly's abemaciclib is being evaluated in combination with Atossa's (Z)-endoxifen in a clinical trial for ER+/HER2- breast cancer.
The involvement of Eli Lilly's abemaciclib in the clinical trial could enhance its market position in breast cancer treatment, potentially benefiting its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50